PHMB PharmaCom BioVet Inc (CE)

In the news release, "PharmaCom BioVet, Inc. and IsoTherapeutics Group, LLC Announces Liquid Brachytherapy Planned for Canine Cancer Treatment Centers," issued Tuesday, October 21, 2008 by PharmaCom BioVet, Inc. (PINKSHEETS: PHMB), we are advised by the company that the headline should read "PharmaCom BioVet, Inc. Announces Direct Injection Liquid Brachytherapy Planned For Their Canine Cancer Treatment Centers" rather than "PharmaCom BioVet, Inc. and IsoTherapeutics Group, LLC Announces Liquid Brachytherapy Planned for Canine Cancer Treatment Centers" as originally issued. We are also advised that the first sentence of the first paragraph should read "PharmaCom Biovet, Inc. is pleased to announce its plans to explore the ground-breaking Liquid Brachytherapy system for the direct injection of therapeutic radioisotopes* for use within its Canine Cancer Treatment Centers." rather than "PharmaCom Biovet, Inc. is pleased to announce its plans with IsoTherapeutics Group, LLC to explore the latest ground-breaking direct injection liquid brachytherapy therapeutic radioisotope procedures* for use within its canine cancer treatment centers." as originally issued. Additionally, a paragraph has been added after the fourth paragraph, and minor revisions have been made throughout the release. Complete corrected text follows.

PharmaCom BioVet, Inc. Announces Direct Injection Liquid Brachytherapy Planned For Their Canine Cancer Treatment Centers

RALEIGH, NC -- October 21, 2008 - PharmaCom BioVet, Inc. (PINKSHEETS: PHMB). PharmaCom BioVet, Inc. is pleased to announce its plans to explore the ground-breaking Liquid Brachytherapy System for the direct injection of therapeutic radioisotopes* for use within its Canine Cancer Treatment Centers.

As part of its plans for state-of-the-art treatment centers for canine lymphoma and other forms of cancer, PharmaCom BioVet, Inc. is greatly encouraged by the latest research results in direct injection of Liquid Brachytherapy radioisotopes into tumors. Recently published collaborative studies in laboratory mice and rats and early clinical success in canines by IsoTherapeutics Group, LLC in Angleton Texas and Valco Instruments Co. Inc. of Houston* demonstrate that these direct injection procedures are superior to previous methods in producing increased efficacy in test cases. These studies have concluded that direct administration of beta-emitting isotopes into tumorous tissues with an easy to prepare, proprietary formulation allows for better targeting of the radioisotope treatment with little to no migration into other non-cancerous tissues.

Recent advances in cancer treatments such as these are fundamental to the scientific basis for PharmaCom BioVet, Inc. "Part of our commitment is to support and harness these cutting-edge methodologies for both cancer treatment and cancer prevention," asserts Gary S. Berthold, President and CEO of PharmaCom BioVet, Inc. "The meaningful research with Liquid Brachytherapy direct injections provides new hope for companion animal lovers and adds to the substantive portfolio of treatment options within our new cancer treatment centers," Berthold added.

Berthold also stated, "While researching treatments for our own pets, we discovered a dynamic convergence within the veterinary and cancer research industries towards providing new treatment technologies for companion animals suffering from cancer. We also discovered a large and growing demand for companion animal cancer care. At the same time we found that there are almost no facilities dedicated to developing and providing these new treatment programs. Based on these factors, we decided to dedicate our lives to creating canine cancer treatments centers around the country," Gary concluded.

PharmaCom BioVet seeks to further the opportunities available to people who have encountered cancer in their companion animals and to offer their animals a better quality of life and longevity. In response to demand and the current lack of adequate cancer treatment options and facilities for animal lovers whose pets are suffering from cancer, PharmaCom BioVet intends to open a network of companion animal cancer care centers throughout North America.

About PharmaCom BioVet, Inc.:

PharmaCom BioVet, Inc. is dedicated to advancing the Veterinary care industry for companion animals by establishing state-of-the-art treatment centers for lymphoma and other forms of cancer throughout the country. The purpose of these centers is to help prolong the quality of life for companion animals with cancer and pursue the potential for complete cure. These centers will also operate under the philosophy of providing a compassionate care environment for both companion animal patients and their owners. For more information, please visit our website www.PharmaComBioVet.com.

About IsoTherapeutics Group, LLC:

The mission of IsoTherapeutics Group, LLC is to develop novel diagnostic and therapeutic agents for the treatment of severe diseases. ITG both develops their our own technologies as well as partners with other companies to help develop pharmaceuticals. Of special interest are radiopharmaceuticals for oncology. In house expertise includes synthetic organic chemistry, chelation chemistry, radiochemistry, diagnostic and therapeutic isotopes, conjugation chemistry, pharmacokinetics, and small animal research models. For more information, please visit our website www.isotherapeutics.com.

DISCLOSURE:

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that are subject to risk and uncertainties, including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in PharmaCom BioVet, Inc.'s filings with the Securities and Exchange Commission. These risks could cause PharmaCom BioVet, Inc.'s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, PharmaCom BioVet, Inc.

*Reference: Jim Simon, Kenneth McMillan, Keith Frank of IsoTherapeutics Group LLC, Angleton, Texas. Stan Stearns, Max Loy of Valco Instruments Co. Inc., Houston, Texas

Contact: Market Ideas, Inc. 877-295-3981 ext. 2 info@marketideasinc.com